阿爾凱默斯 ALKS 深 滬
等待開盤 10-23 09:30:00 美东时间
31.09
-0.360
-1.14%
華盛通- 最 高32.02
- 今 開30.00
- 成交量 432.58万股
- 最 低 29.93
- 昨 收 31.45
- 總市值 51.30亿
- 52周最高 36.45
- 市盈率 靜 14.33
- 換手率 2.62%
- 52周最低 25.165
- 委 比 74.23%
- 總股本 1.65亿
- 歷史最高 79.041
- 量 比 2.42
- 振 幅 6.65%
- 歷史最低 10.311
- 每 手 1
- 風險率 2.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
今天 03:18
Avadel settles with Jazz Pharma; agrees to be acquired by Alkermes
Irish biotech Alkermes (NASDAQ:ALKS) has agreed to acquire sleep drug developer Avadel Pharmaceuticals (NASDAQ:AVDL) for up to $20.00 per share in an all-cash deal worth $2.1B, the companies announced...
10-22 19:20
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH J...
10-22 19:00
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Alkermes upgraded at RBC Capital Markets ahead of key catalyst
Alkermes (NASDAQ:ALKS) shares spiked on Friday after RBC Capital Markets upgraded the Irish biotech to Outperform from Sector Perform, citing a compelling buying opportunity ahead of a key late-stage ...
09-26 23:12
RBC Capital Upgrades Alkermes to Outperform, Raises Price Target to $44
RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price target from $42 to $44.
09-26 19:40
Global Psychotic Disorders Market Poised For Significant Growth
The global market for medications addressing psychotic disorders is projected t...
09-16 17:09
Alkermes Partners with Amneal for VIVITROL® Distribution
Alkermes ( ($ALKS) ) just unveiled an announcement. On September 9, 2025, Alker...
09-13 05:21
Alkermes appoints new CFO
Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS), effective September 15, 2025. Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics (ALDX), ...
09-12 21:08
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Diso...
09-11 19:00
